A global consortium led by Adaptvac ApS aims to design and test a new vaccine that could offer broad protection against several filoviruses, including Zaire ebolavirus, Sudan ebolavirus and Marburg virus.

DUBLIN – Bavarian Nordic A/S, Europe’s largest independent vaccine developer, is placing a bet on virus-like particle (VLP) technology as a potentially useful contribution to the desperate global effort to push back against SARS-CoV-2.